FOLH1 and metastatic neoplasm: Systemic treatments with either taxane-based chemotherapy or novel antiandrogen drugs are approved for M1 HSPC with metastatic disease on CIT [7,8], while PSMA-PET/CT is now detecting metastatic disease in an earlier stage, previously considered M0.